DAY 31

Health & Longevity: Cancer Prevention Science
Cancer Prevention — Mechanisms, Modifiable Risk, Screening & Overdiagnosis

2026-06-19 · BigCat's Vitality Protocol

This issue's stance: cancer is neither a "luck disease" nor a "the more you screen, the safer you are" problem. It is an evolutionary process open to probabilistic intervention—roughly 30–50% is preventable, yet screening itself carries the real harm of overdiagnosis. Understand the mechanism and you can decide without being hijacked by fear.

PREV · CARCINOGENESIS

Evidence: mechanistic / expert consensus

Carcinogenesis: cancer is an evolutionary accumulation of mutations

Cancer as Somatic Evolution

Bottom line

Cancer is not a single event but a cell progressively accumulating multiple driver mutations (typically 2–8) until it escapes the body's control. This explains why age is the single strongest risk factor—the longer you live, the more mutations pile up.

Science + mechanism

Hanahan & Weinberg's "Hallmarks of Cancer" is the common language for understanding cancer: core capabilities include sustained proliferation, evading growth suppressors, resisting apoptosis, replicative immortality, inducing angiogenesis, invasion/metastasis, metabolic reprogramming (the Warburg effect), and evading immune destruction, with two enabling characteristics—genomic instability and tumor-promoting inflammation. Key insight: cancer follows Darwinian selection—mutant cells compete, expand, and adapt to treatment within the body, which is also the root of resistance and metastasis.

Actionable protocol

You cannot "eat something to erase mutations," but you can lower the mutation rate and the pro-cancer environment: ① reduce DNA-damaging exposures (smoke, UV, radiation, the alcohol metabolite acetaldehyde); ② suppress chronic inflammation; ③ maintain metabolic health (hyperinsulinemia/obesity drive proliferation via IGF-1 and inflammation); ④ support immune surveillance (sleep and exercise raise NK-cell activity). These overlap heavily with general longevity protocols—anti-cancer and anti-aging share the same underlying levers.

For women + common myths

Hereditary breast/ovarian cancer syndromes (BRCA1/2) raise carriers' lifetime breast-cancer risk to 60–70% and ovarian to 15–40%. If your family has breast cancer before 50, ovarian cancer, or multiple cancers, genetic counseling and testing are worthwhile—they materially change the age you should start screening and your prevention strategy.

Myths: ① "Cancer is all inherited"—only ~5–10% are hereditary germline mutations; the vast majority are acquired somatic mutations; ② "An acidic body causes cancer"—pseudoscience; blood pH is tightly regulated and has no causal link to cancer.

Key references

• Hanahan D, Weinberg RA. Cell. 2011;144(5):646-674. · Hanahan D. Cancer Discov. 2022;12(1):31-46.
• Peter Attia, Outlive, Ch.8 "Cancer".

Try this week + reflection

THIS WEEK

Draw a cancer family history of close relatives: who, which cancer, age at diagnosis. Onset before 50 or multiple cancers in one lineage is a signal for genetic counseling. Reflection: if cancer is a probabilistic evolutionary process rather than a yes/no switch, is the question "will I get cancer?" itself ill-posed?

PREV · MODIFIABLE RISK

Evidence: large cohorts / IARC classification

Modifiable risk: 30–50% of cancers are preventable

Up to Half Are Preventable

Bottom line

By WCRF/AICR estimates, about 30–50% of cancers are driven by modifiable factors. The biggest levers, ranked clearly: quit smoking > control obesity/metabolism > limit alcohol > prevent infections (HPV/HBV/H. pylori) > sun protection > regular exercise.

Science + mechanism

Smoking accounts for about 30% of all cancer deaths—the single largest modifiable factor. Alcohol is an IARC Group 1 carcinogen with no safe dose—acetaldehyde directly damages DNA, linked to breast, colorectal, liver, and esophageal cancers. Obesity is causally tied to at least 13 cancers (IARC 2016) via hyperinsulinemia/IGF-1, inflammation, and elevated estrogen. About 13% of cancers are caused by infections (HPV→cervix, HBV/HCV→liver, H. pylori→stomach). Exercise lowers colon cancer (~−20%) and breast cancer risk by reducing insulin and modulating immunity.

Actionable protocol

Lever	Evidence	Concrete action
Quit smoking	Group 1, largest single	Full cessation, incl. vaping & secondhand
Limit alcohol	Group 1, dose-related	Less is better; no "healthy dose"
HPV vaccine	RCT + cohort	Ages 9–45, prefer 9-valent
Weight/metabolism	13 cancers	Healthy body comp, control waist
Exercise	Large cohorts	≥150 min/wk moderate intensity
Sun protection	Melanoma	SPF30+, avoid midday exposure

Hepatitis-B vaccination and H. pylori testing/eradication are underrated, high-value anti-cancer measures.

For women + common myths

The alcohol–breast cancer link is clear: one drink a day (~10 g ethanol) raises breast cancer risk by ~7–10% (Million Women Study)—the point the "moderate drinking is good for you" narrative most needs to retire. HPV vaccination plus regular cervical screening can bring cervical cancer close to elimination (Lei 2020, NEJM). Breastfeeding lowers breast cancer risk ~4% per 12 months.

Myths: ① "Red wine fights cancer"—the cardiovascular benefit is overstated and it is purely harmful for cancer; ② "Superfoods prevent cancer"—no single food does; what matters is the overall dietary pattern (more plants, less processed meat, less alcohol); ③ "Sunscreen causes cancer"—evidence points to a lack of sun protection causing skin cancer, not the reverse.

Key references

• World Cancer Research Fund/AICR. Diet, Nutrition, Physical Activity and Cancer (2018).
• Lei J, et al. N Engl J Med. 2020;383:1340-1348. · Allen NE, et al. (Million Women Study) JNCI. 2009;101(5):296-305.

Try this week + reflection

THIS WEEK

Check two things: ① your own and your children's HPV/hepatitis-B vaccination status; ② if you drink, honestly log a week's actual intake (most people underestimate). Reflection: we'll pay for dubious supplements yet give a Group 1 carcinogen—alcohol—a pass. Where does that asymmetry come from?

PREV · SCREENING

Evidence: RCT / USPSTF consensus

Screening: only a few work

Benefits and Real Harms

Bottom line

Screening is not "more is better." Only a few have RCT evidence of actually lowering mortality: colorectal, cervical, lung (LDCT in high-risk smokers), and breast (moderate evidence). Most other "cancer check-up" packages do more harm than good.

Science + mechanism

Effective screening requires: the disease is common, has a detectable preclinical phase, early treatment improves outcomes, and the test is accurate. The endpoint must be mortality, not "5-year survival"—lead-time bias and length bias inflate survival even when early detection doesn't extend life. Proven effective: colonoscopy (removes adenomas, lowers both incidence and death); cervical HPV/cytology (cuts cervical cancer death >80%); lung LDCT (NLST cut lung cancer death 20%); mammography (cuts death ~20%, but with overdiagnosis).

Actionable protocol

Screening	Who	Frequency
Colorectal	Ages 45–75	Colonoscopy q10y or FIT yearly
Cervical	Ages 25/30–65	HPV test every 5 years
Breast	Ages 40–74	Mammography every 1–2 years
Lung LDCT	50–80, heavy smoking hx	Yearly (within 15 yrs of quitting)

Principle: do the few right things by guideline, and do them well—better than randomly adding a pile of unproven tests. Before each screen, know its benefit magnitude and false-positive rate.

For women + common myths

The starting age for breast screening has long been debated: in 2024 the USPSTF moved its recommendation from 50 to begin at 40, every 2 years. Dense breasts (common in Asian women) reduce mammographic sensitivity—discuss supplemental ultrasound/MRI with your doctor. HPV self-sampling now improves access.

Myths: ① "Whole-body CT/PET is the most thorough cancer check-up"—high radiation plus many false positives and "incidentalomas" trigger cascades of over-testing; recommended by no guideline for asymptomatic people; ② "Tumor markers (CEA, CA125) are good for screening healthy people"—high false-positive rate, poor specificity; ③ "High 5-year survival = screening saved a life"—possibly just a bias artifact.

Key references

• US Preventive Services Task Force screening recommendations (uspreventiveservicestaskforce.org).
• National Lung Screening Trial. N Engl J Med. 2011;365:395-409. · Welch HG, et al. N Engl J Med. 2016;375:1438-1447.

Try this week + reflection

THIS WEEK

Against the USPSTF or your national guidelines, draw up a screening list by your age, sex, and smoking history, and book the next one due. Reflection: when an ad says "early detection, early treatment," does it tell you how many people must be screened to prevent one death (NNS)?

PREV · OVERDIAGNOSIS

Evidence: population cohorts / modeling

The overdiagnosis dilemma: detected doesn't mean treat

Detecting Cancers That Never Harm

Bottom line

Overdiagnosis means detecting "cancers" that would never cause symptoms or death in your lifetime. The classic cases are thyroid cancer, some low-risk prostate cancers, and breast ductal carcinoma in situ (DCIS)—and the overtreatment that follows often harms more than it helps.

Science + mechanism

The most dramatic example is South Korea's thyroid cancer "screening tsunami": as ultrasound screening spread, incidence rose ~15-fold over 15 years while mortality didn't budge (Ahn 2014, NEJM)—most detected were never-lethal micropapillary cancers. Prostate PSA is the same: many indolent cancers are found, yet patients suffer incontinence and erectile dysfunction after surgery/radiation. Key insight: "cancer" is a pathology label, not synonymous with "a disease that will kill you." The remedy is active surveillance—low-risk prostate cancers and tiny thyroid cancers can be watched rather than excised immediately, now written into mainstream guidelines.

Actionable protocol

When a screen finds an "abnormality / early cancer," ask your doctor three questions: ① Will this finding change the treatment plan? ② How likely is it that this is overdiagnosis? ③ Is "active surveillance" an option? For low-risk prostate cancer and ≤1 cm papillary thyroid cancer, active surveillance is often the evidence-based, safe first choice, sparing irreversible treatment side effects.

For women + common myths

Thyroid cancer is far more common in women (about 3:1), so they are more likely to be the targets of overdiagnosis—when a small thyroid nodule is found, assess rather than panic. A meaningful fraction of breast DCIS may never progress, so whether to do surgery/radiation deserves fully informed decision-making (worth knowing about low-risk DCIS surveillance trials such as COMET).

Myths: ① "Early detection always saves lives"—untrue for indolent tumors, where it brings pure harm; ② "Cutting it out brings peace of mind"—overtreatment has real, sometimes irreversible complications; ③ "A nodule = cancer"—the vast majority of thyroid and breast nodules are benign.

Key references

• Ahn HS, et al. N Engl J Med. 2014;371:1765-1767. · Welch HG, Black WC. JNCI. 2010;102(9):605-613.
• Hamdy FC, et al. (ProtecT) N Engl J Med. 2016;375:1415-1424.

Try this week + reflection

THIS WEEK

Save the "three screening questions" above to your phone's notes, and pull them out next time any check-up finds something. Reflection: when "early detection" causes net harm for certain cancers, is our gut feeling that "more cancer screening is always better" real knowledge—or an instinct trained by marketing and fear?

🔬 Reflections

① If 30–50% of cancers are preventable, why is public investment still overwhelmingly tilted toward treatment over prevention?

Prevention's payoff is diffuse, delayed, and hard to credit—lowering a population's risk can't point to "who was saved," unlike a surgery with an identifiable beneficiary. Incentives, fee-for-service payment, and the commercial return on new drugs all favor the treatment end. Prevention also needs cross-sector, long-term coordination (tobacco, food, environment) whose payoff outlasts any term of office. The result: we'd rather pay to "rescue drowning people" than "build a railing upstream."

② If the word "cancer" itself conflates indolent lesions with lethal disease, should low-risk lesions be renamed?

This is a genuine academic debate. Some experts propose dropping "carcinoma" from certain low-risk lesions (e.g., low-risk DCIS, micropapillary thyroid cancer), using neutral terms like "indolent epithelial lesion" to reduce overtreatment. Opponents worry patients will become complacent and skip follow-up. Naming is not just language—it shapes fear, decisions, and treatment intensity. A reminder that a diagnostic label carries social weight far beyond biology.

③ Will multi-cancer early-detection blood tests (cfDNA "liquid biopsy") become saviors, or amplifiers of overdiagnosis?

Both are possible. One tube of blood checking many cancers is alluring, but if sensitivity skews toward detecting already-indolent tumors, it only manufactures more "don't-know-whether-to-treat" findings, amplifying overdiagnosis and anxiety. The key is whether RCTs show it lowers mortality (not merely "finds more cancers"). Until hard endpoints arrive, commercial rollout to healthy populations warrants caution—advanced technology doesn't guarantee net benefit is positive.

④ Personal "anti-cancer" overlaps heavily with general longevity protocols—so is "cancer-specific prevention" even a separate question?

Largely it isn't. Not smoking, limiting alcohol, controlling metabolism, regular exercise, protecting sleep, reducing inflammation—this set of levers simultaneously lowers cardiovascular, metabolic, neurodegenerative, and cancer risk. Truly "cancer-specific" measures are few: HPV/HBV vaccination, H. pylori eradication, sun protection, and guideline-based screening. Pragmatic conclusion: invest in the universal longevity foundation, then layer on these few specifics—far better than chasing "anti-cancer superfoods."